RxDoctor Payments Data

Rachael Ramos

Family · Carmel, INNPI 1396226692

Payments from drug & device makers

$2,363in general payments, 2019–2025

Across 122 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Medtronic$288
  • AbbVie$256
  • Echosens North America, Inc.$149
  • Rhythm Pharmaceuticals, Inc.$102
  • Nestle Healthcare Nutrition Inc.$85
  • plus $232 from 5 others

What the payments were for

  • Food & beverage$2,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,363 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$20,943
Medicare patients
152
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase20$61,528
WegovySemaglutide18$24,091
MounjaroTirzepatide15$12,895
Dexlansoprazole DrDexlansoprazole21$5,846
Omeprazole283$3,606
Sucralfate85$2,693
Famotidine131$1,842
Pantoprazole Sodium137$1,564
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)92$1,235
Ondansetron OdtOndansetron21$491
Metformin Hcl ErMetformin Hcl13$172
Topiramate14$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$256$61,52820 claims
Novo NordiskWegovy$1,251$24,09118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →